30Jan
Biocartis – Breast Cancer Portfolio
Last updated: 21st March, 2024
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Biocartis is pleased to launch a new breast cancer portfolio: Idylla™ PIK3CA-AKT1 Mutation Assay, APIS Breast Cancer Subtyping Kit and APIS ESR1 Mutations Kit.
1 Research use only (RUO)